For the quarter ending 2026-03-31, MAZE made $20,000,000 in revenue. -$24,208,000 in net income. Net profit margin of -121.04%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| License revenue | 20,000,000 | - | - | 0 |
| Research and development | 34,148,000 | 28,501,000* | 25,190,000 | 28,108,000 |
| General and administrative | 12,405,000 | 10,239,500* | 7,775,000 | 8,366,000 |
| Total operating expenses | 46,553,000 | 38,740,500 | 32,965,000 | 36,474,000 |
| Loss from operations | -26,553,000 | -38,740,500* | -32,965,000 | -36,474,000 |
| Interest and other income, net | 3,211,000 | 3,269,500* | 2,878,000 | 2,795,000 |
| (loss) income before income tax expense | - | -35,471,000 | -30,087,000 | -33,679,000 |
| Interest expense | 866,000 | - | - | - |
| Income tax expense | - | - | - | 0 |
| Total other income, net | 2,345,000 | - | - | - |
| Net loss | -24,208,000 | -35,471,000 | -30,087,000 | -33,679,000 |
| Basic EPS | -0.45 | -0.901 | -0.66 | -0.77 |
| Diluted EPS | -0.45 | -0.901 | -0.66 | -0.77 |
| Basic Average Shares | 53,897,216 | 39,351,074 | 45,779,577 | 43,797,421 |
| Diluted Average Shares | 53,897,216 | 39,351,074 | 45,779,577 | 43,797,421 |
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)